- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2012
- Public Summary Document (PSD) November 2012 PBAC Meeting - PDF
Pazopanib – November 2012
Pazopanib, tablets, 200 mg and 400 mg (as hydrochloride), Votrient®
Last updated
8 November 2023